logo
logo
Sign in

Growth Hormone Deficiency Market

avatar
Ankit Nigam
Growth Hormone Deficiency Market

Growth hormone deficiency is a condition where the pituitary gland is unable to make enough growth hormone. It can be caused by damage to the pituitary gland or another gland called the hypothalamus. The injury can occur before birth (congenital), or during or after birth (acquired). A third category has no known or diagnosable cause (idiopathic). Growth hormone deficiency may be caused by a tumor in the brain. These tumors are normally located at the site of the pituitary gland or the nearby hypothalamus region of the brain. In children and adults, serious head injuries, infections, and radiation treatments can also cause Growth hormone deficiency, which is known as acquired Growth hormone deficiency (AGHD). However, in rare cases, Growth hormone deficiency can be part of a genetic syndrome such as Turner syndrome and Prader-Willi syndrome. Additionally, in many cases, the cause of Growth hormone deficiency is not known or idiopathic.

DelveInsight's "Growth Hormone Deficiency Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Growth Hormone Deficiency, historical and forecasted epidemiology as well as the Growth Hormone Deficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of Growth hormone deficiency Market Report Facts are:

  • As per the study by Bonfig et al. (2019) titled “Mini Review/Commentary: Growth Hormone Treatment in Children with Type 1 Diabetes,” the prevalence of GHD ranges between 1/3500 and 1/8700 in Germany.
  • According to the Boston Children’s Hospital, about 1 in 4,000–10,000 children have GHD.
  • Several secondary sources suggest that GHD is slightly more prevalent in males than in females.
  • According to the Growth Hormone Foundation estimates, more than 50,000 adults in the United States are growth hormone deficient, and 6,000 new cases are reported each year, including GHD children who transition to GHD as an adult.
  • It is estimated that in the adult UK population at any given time, approximately 1 in every 10,000 people will have adult-onset GHD, which works out to approximately 12,600 adults with GHD in England and Wales.

Request for Free Sample Report: https://www.delveinsight.com/sample-request/growth-hormone-deficiency-ghd-market

Some of Growth hormone deficiency Companies are:

  • Ascendis Pharma
  • Pfizer
  • Opko
  • Lumos Pharma
  • Novo Nordisk
  • Ipsen
  • Pfizer
  • And Many Others

Request for Free Sample Report: https://www.delveinsight.com/sample-request/growth-hormone-deficiency-ghd-market

Scope of the Growth hormone deficiency Report:

  • The report covers the descriptive overview of Growth Hormone Deficiency, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Growth Hormone Deficiency epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Growth Hormone Deficiency are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Growth Hormone Deficiency market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Growth Hormone Deficiency market

Some of Growth hormone deficiency therapies are:

  • TransCon hGH
  • Somatrogon
  • LUM-201
  • Norditropin
  • Sogroya (somapacitan)
  • Increlex
  • Genotropin
  • And Many Others

Request for Free Sample Report: https://www.delveinsight.com/sample-request/growth-hormone-deficiency-ghd-market

Table of Contents:

  1. Key Insights
  2. Executive Summary of Growth Hormone Deficiency
  3. Competitive Intelligence Analysis for Growth Hormone Deficiency
  4. Growth Hormone Deficiency: Market Overview at a Glance
  5. Growth Hormone Deficiency: Disease Background and Overview
  6. Patient Journey
  7. Growth Hormone Deficiency Epidemiology and Patient Population
  8. Treatment Algorithm, Current Treatment, and Medical Practices
  9. Unmet Needs
  10. Key Endpoints of Growth Hormone Deficiency Treatment
  11. Marketed Products

List to be continued in report

  1. Emerging Therapies

List to be continued in report

  1. Growth Hormone Deficiency: Seven Major Market Analysis
  2. Attribute analysis
  3. 7MM: Market Outlook
  4. Access and Reimbursement Overview of Growth Hormone Deficiency
  5. KOL Views
  6. Market Drivers
  7. Market Barriers
  8. Appendix
  9. DelveInsight Capabilities
  10. Disclaimer
  11. About DelveInsight

Request for Detailed TOC: https://www.delveinsight.com/sample-request/growth-hormone-deficiency-ghd-market

Other Links:

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Contact us
Ankit Nigam
[email protected]
+91-9650213330
https://www.delveinsight.com/
Connect With Us at:
LinkedIn | Facebook | Twitter

Request for Free Sample Report: https://www.delveinsight.com/sample-request/growth-hormone-deficiency-ghd-market

 

collect
0
avatar
Ankit Nigam
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more